Investigators found that incident osteopenia and osteoporosis are significantly higher in young survivors of breast cancer.
Among breast cancer patients on adjuvant trastuzumab, lisinopril and carvedilol reduced cardiotoxicity, but only for those in the anthracycline cohort.
Researchers find that surgical decision making is often driven by factors beyond extent of disease.
CARB-BC predicted grade 3 to 5 adverse events, dose modifications, and hospitalizations.
The immune marker PD1 may be prognostic for survival in patients with TNBC who achieve a pathologic complete response after neoadjuvant therapy.
The rates of adverse events seen across dose schedule type for patients who underwent IMRT were roughly similar.
Black women with the most common type of breast cancer had worse clinical outcomes compared with white women, despite receiving similar systemic therapy.
Alpelisib Plus Fulvestrant Continues to Show Improved PFS in PIK3CA-Mutant, HR+, HER2- Advanced Breast CancerDecember 07, 2018
Alpelisib plus fulvestrant consistently resulted in prolonged PFS among patients with HR-positive, HER2-negative advanced breast cancer who also had PIK3CA mutations.
Partial-breast irradiation failed to meet protocol-defined measures for equivalence.
CTC count may help guide the decision between first-line chemotherapy or endocrine therapy in ER-positive, HER-negative metastatic breast cancer.
The extension of adjuvant anastrozole to 10 years of treatment showed higher rates of DFS and distant DFS, but did not improve overall survival.
The addition of palbociclib to letrozole did not show clinical benefit as a neoadjuvant therapy, but did enhance the suppression of malignant cell proliferation.
The results of the TAM-01 phase III trial suggest that the dose of tamoxifen can be lowered to achieve better safety without compromising efficacy.
Adjuvant chemotherapy was linked to improved overall survival in older adults with breast cancer.
A meta-analysis showed that breast cancer patients who have a pathologic complete response after neoadjuvant chemotherapy may not benefit from adjuvant chemotherapy.
Adjuvant trastuzumab emtansine showed improved invasive disease-free survival compared with trastuzumab in HER2-positive early breast cancer.
New research may help identify new candidate targets and stratify patients eligible for innovative therapies.
Adjuvant capecitabine provided no survival benefit for patients with early triple-negative breast cancer, except for those with nonbasal-like disease.
Researchers reported early findings of a trial evaluating chimeric antigen receptor T-cell therapy for a subset of triple-negative breast cancer patients.
Valuable insights revealed from the characterization of the tumor microenvironment of thousands of early and metastatic breast cancer cells.
PD-L1 expression by tumor-infiltrating immune cells was found to be the most predictive biomarker for survival outcomes for patients with advanced TNBC in the IMpassion130 trial.
Researchers Identify Genomic Alterations That Drive Disease Progression and Endocrine Resistance in Invasive Lobular CancerDecember 05, 2018
Results from the largest metastatic ILC series in which matched primary tumor and metastases samples were interrogated.
The San Antonio Breast Cancer Symposium will take place from December 4-8 at the Henry B. Gonzalez Convention Center in Texas.
Sixty patients with early stage breast cancer who underwent surgery and then were treated per national guidelines were included in the pilot study.
The findings suggest the consideration of long-term use of statins for patients with breast cancer.
Women and men were found to react differently to treatment with chemotherapy, although gender-based survival differences were not observed.
High-risk early breast cancer patients with circulating tumor cells 2 years after chemotherapy had greater risk of recurrence. Possible interventions are needed.
Among 4 specific breast cancer stages, T2N1 cancers showed the highest risk for local recurrence, regional recurrence, and distant metastases within 10 years from diagnosis.
By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.
One-view digital breast tomosynthesis with a reduced compression force detected breast cancer with higher sensitivity and lower specificity than 2-view digital mammography.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- CAR-T Trial for Triple-Negative Breast Cancer Under Way
- Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Phase 3 GEICAM/CIBOMA Results: Adjuvant Capecitabine in Triple-Negative Breast Cancer
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma
- Younger Breast Cancer Patients at Higher Risk for Osteoporosis
- Molecular Mechanisms Underlying Immunosurveillance in Multiple Myeloma Identified
- Gly101Val Mutation Directly Causes Resistance to Venetoclax
- Can Treatments for Childhood ALL Alter the Gut Microbiome?